MedPath

insulin

Generic Name
insulin
Clinical Trials
Related News

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

Phase 3
Completed
Conditions
Hyperglycemia
Covid19
Interventions
First Posted Date
2020-09-09
Last Posted Date
2021-03-23
Lead Sponsor
Hospital Regional de Alta Especialidad del Bajio
Target Recruit Count
70
Registration Number
NCT04542213
Locations
🇲🇽

Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Phase 4
Active, not recruiting
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Device: Continuous glucose monitor (CGM)
First Posted Date
2020-08-31
Last Posted Date
2025-03-25
Lead Sponsor
Jagdeesh Ullal
Target Recruit Count
13
Registration Number
NCT04533646
Locations
🇺🇸

University of Pittsburgh Medical Center, Center for Diabetes and Endocrinology, Pittsburgh, Pennsylvania, United States

Effect of Insulin on Wound Healing-A Randomized Controlled Trial

Phase 4
Conditions
Wound Heal
Interventions
First Posted Date
2020-05-18
Last Posted Date
2020-05-19
Lead Sponsor
Ministry of Health, Bahrain
Target Recruit Count
30
Registration Number
NCT04390815

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Phase 4
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2020-05-13
Last Posted Date
2022-02-16
Lead Sponsor
Assiut University
Target Recruit Count
100
Registration Number
NCT04385589
Locations
🇪🇬

Assiut University, Assuan, Egypt

Combined Effect of Insulin and Sodium Hyaluronate Injection Guided by Ultrasound in Carpal Tunnel Syndrome

Early Phase 1
Conditions
Carpal Tunnel Syndrome
Interventions
Device: Ultrasound
First Posted Date
2019-10-29
Last Posted Date
2019-10-29
Lead Sponsor
Assiut University
Target Recruit Count
90
Registration Number
NCT04142411
Locations
🇪🇬

Medicine, Assiut, Egypt

Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide

Not Applicable
Conditions
Diabetic Neuropathic Pain
Interventions
First Posted Date
2019-10-24
Last Posted Date
2019-10-25
Lead Sponsor
Fudan University
Target Recruit Count
60
Registration Number
NCT04137328

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Early Phase 1
Withdrawn
Conditions
Type 1 Diabetes
Insulin Sensitivity/Resistance
Interventions
Drug: Dextrose 20 % in Water
First Posted Date
2019-10-21
Last Posted Date
2022-03-22
Lead Sponsor
University of Virginia
Registration Number
NCT04133922
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Insulin Lispro (Humalog U-100)
First Posted Date
2019-09-24
Last Posted Date
2019-09-24
Lead Sponsor
Dance Biopharm Inc.
Target Recruit Count
24
Registration Number
NCT04100473
Locations
🇩🇪

Profil Mainz, Mainz, Malakoff-Passage, Germany

Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes

Phase 1
Terminated
Conditions
Hyperglycemia, Postprandial
Type 1 Diabetes
Interventions
First Posted Date
2019-09-06
Last Posted Date
2022-10-07
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
1
Registration Number
NCT04079881
Locations
🇺🇸

Washington University in St Louis, Saint Louis, Missouri, United States

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: GLP-1 receptor agonist
First Posted Date
2019-07-26
Last Posted Date
2020-07-09
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
20000
Registration Number
NCT04034524
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy